VJHemOnc is committed to improving our service to you

iwNHL 2015 | iwNHL 2015 roundtable: Day 2 highlights – PI3K inhibitors

VJHemOnc is committed to improving our service to you

John Gribben and Wyndham Wilson

John Gribben, MD, DSc, FRCPath, FRCP FMedSci, of Barts and The London School of Medicine and Dentistry, London, UK, chairs a discussion with Wyndham Wilson, MD, PhD, on the highlights from the second day of the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting. They review the clinical development of inhibitors targeting the phosphoinositide 3-kinase (PI3K) pathway, as single agents and in combination with other therapies, for the treatment of patients with non-Hodgkin lymphoma.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter